Daruka Mahadevan

5PUBLICATIONS
17CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Breelyn A Wilky, Gary K Schwartz, Michael S Gordon

|Aug 25, 2019
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.

Daruka Mahadevan, Mark C Lanasa, Charles Farber

|Aug 16, 2017
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.

Michael A Badruddoja, Marjorie Pazzi, Abhay Sanan

|Mar 15, 2017
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.

D Mahadevan, Monica Mita, Donald Richards

Pageof 1

Frequent Collaborators

2 joint publications

Thomas Scully

2 joint publications

Michael Malek Ahmadi

1 joint publications

Breelyn A Wilky

1 joint publications

Gary K Schwartz